Pearl Therapeutics

pearltherapeutics.com

Pearl Therapeutics, an AstraZeneca group company, was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

DIME RELEASES TOOLKITS TO IMPROVE SENSOR DATA INTEGRATION AND POWER BETTER, FASTER GLOBAL HEALTHCARE AND RESEARCH

Digital Medicine Society | July 18, 2022

news image

Today, the Digital Medicine Society released the Sensor Data Integrations Toolkits, four comprehensive toolkits to guide data producers, processors, and consumers to use the influx of data from the increased use of wearables and digital sensing products at scale. These resources are based on the Sensor Data Integrations project, comprised of healthcare leaders from Amazon Web Services Oracle, the Moffitt Cancer Center, Takeda, the US Department of Veterans Affairs and more. These toolkits will h...

Read More

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

news image

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More

Business Insights, PHARMACY MARKET

PATHAI ANNOUNCES PATHEXPLORE, AN AI-POWERED PATHOLOGY PANEL TO UNLOCK UNTAPPED INSIGHTS FROM THE TUMOR MICROENVIRONMENT

Prnewswire | April 05, 2023

news image

PathAI, a global leader in AI-powered pathology, announced the launch of PathExplore™, the world's first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore1 spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next p...

Read More

VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER

Business Wire | February 17, 2020

news image

Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, h...

Read More
news image

Business Insights

DIME RELEASES TOOLKITS TO IMPROVE SENSOR DATA INTEGRATION AND POWER BETTER, FASTER GLOBAL HEALTHCARE AND RESEARCH

Digital Medicine Society | July 18, 2022

Today, the Digital Medicine Society released the Sensor Data Integrations Toolkits, four comprehensive toolkits to guide data producers, processors, and consumers to use the influx of data from the increased use of wearables and digital sensing products at scale. These resources are based on the Sensor Data Integrations project, comprised of healthcare leaders from Amazon Web Services Oracle, the Moffitt Cancer Center, Takeda, the US Department of Veterans Affairs and more. These toolkits will h...

Read More
news image

Pharma Tech

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

Read More
news image

Business Insights, PHARMACY MARKET

PATHAI ANNOUNCES PATHEXPLORE, AN AI-POWERED PATHOLOGY PANEL TO UNLOCK UNTAPPED INSIGHTS FROM THE TUMOR MICROENVIRONMENT

Prnewswire | April 05, 2023

PathAI, a global leader in AI-powered pathology, announced the launch of PathExplore™, the world's first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore1 spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next p...

Read More
news image

VIFOR PHARMA ACQUIRES PRIORITY REVIEW VOUCHER

Business Wire | February 17, 2020

Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). Vifor Pharma Group is a global speciality pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, h...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us